Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1944 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| mRNA-1944 | EXPERIMENTAL | Escalating dose levels |
| Placebo | PLACEBO_COMPARATOR | Saline |
| Name | Type | Description |
|---|---|---|
| mRNA-1944 | BIOLOGICAL | mRNA encoding Chikungunya antibody |
| Placebo | OTHER | Saline |
Inclusion Criteria: * Male or female ≥ 18 and ≤ 50 years of age * Weight of 50 to 100 kg, inclusive * In good general health as determined by medical history, clinical laboratory assessments, ECG results, vital sign measurements, and physical examination findings at screening * Has access to consis...
mRNA-1944 is an investigational messenger RNA (mRNA) therapeutic being developed for the prevention of Chikungunya virus infection. It is designed to encode a monoclonal antibody that targets the virus, though it is not yet approved and remains in clinical development.
mRNA-1944 is being developed by Moderna, Inc., a biotechnology company publicly traded under the ticker symbol MRNA on the Nasdaq stock exchange. The company is conducting clinical research on this investigational mRNA-based monoclonal antibody candidate.
mRNA-1944 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the candidate remains under evaluation for the prevention of Chikungunya virus infection.
mRNA-1944 has one completed Phase 1 clinical trial, identified as NCT03829384. The study, titled 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults,' enrolled 39 participants in the United States and evaluated the drug in healthy volunteers.
mRNA-1944 is an mRNA-based monoclonal antibody therapy. It works by instructing cells to produce a monoclonal antibody that targets the Chikungunya virus, potentially providing protection against infection. This mechanism is based on the drug's design as an mRNA-encoded antibody.
No, mRNA-1944 is not a traditional vaccine. It is an mRNA-encoded monoclonal antibody designed to deliver pre-formed antibodies for the prevention of Chikungunya virus infection, rather than stimulating the immune system to produce its own antibodies like a conventional vaccine.